PIM-Targeted PROTACs Available for Licensing or Collaboration: Attend April Webinar to Learn More

All are invited to attend  the NCI Technology Transfer Center’s upcoming technology opportunity webinar entitled, “Proteolysis Targeting Chimeras (PROTACs) Targeting PIM Kinase for the Treatment of Cancer,” on April 24, from 11:00 a.m. to 12:00 p.m. The inventor, Senior Investigator, Dr. John Brognard, Laboratory of Cell and Developmental Signaling, NCI, will provide an overview of the technology, discuss its advantages over current small molecule PIM kinase inhibitors and answer questions.

Attendees will learn about a new family of Proteolysis Targeting Chimeras (PROTACS) that selectively target Proviral Integration for the Moloney murine leukemia virus (PIM) kinases which have roles in cancer development and mediating resistance to radio and chemotherapy; and is overexpressed in multiple cancers.  Several small molecule PIM kinase inhibitors have had minimal effect in suppressing cancer phenotypes due to the  PIM kinase inhibitors promoting intrinsic resistance.  By contrast, these PIM targeted PROTACs suppress PIM kinase activity by completely degrading the PIM kinase proteins – intrinsic resistance is therefore avoided.   

The Technology Analysis and Marketing Unit, part of NCI TTC, organizes and hosts technology opportunity webinars throughout the year. These one-hour webinars provide an opportunity for inventors to present a technology to an audience of potential industry partners and licensees.

Learn more about the technology and how to register.